ArticleInternational journal of molecular sciences2023

The LIFR Inhibitor EC359 Effectively Targets Type II Endometrial Cancer by Blocking LIF/LIFR Oncogenic Signaling.

Nicole Spencer et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.